Valuation: COSMO Pharmaceuticals SA

Market Cap 1.1B 1.27B 1.03B 943M 1.78B 121B 1.8B 12.1B 4.73B 60.28B 4.76B 4.66B 200B P/E 2026 *
952x
P/E 2027 * 22.1x
Enterprise Value 1.07B 1.23B 1B 918M 1.74B 117B 1.76B 11.79B 4.61B 58.72B 4.64B 4.54B 195B EV / Sales 2026 *
10.1x
EV / Sales 2027 * 6.09x
Free-Float
40.52%
Yield 2026 *
3.32%
Yield 2027 * 3.53%

Last Transcript: COSMO Pharmaceuticals SA

Manager TitleAgeSince
Chief Executive Officer 52 2024-05-23
Director of Finance/CFO - 2024-11-10
Chief Tech/Sci/R&D Officer 53 2008-12-31
Director TitleAgeSince
Chairman 71 2013-12-31
Director/Board Member 71 2012-03-31
Director/Board Member 54 2024-05-23
Change 5-day change 1-year change 3-year change Capi.($)
+8.62%-8.60%+45.08%+148.21% 995B
+0.68%-4.42%+49.05%+50.81% 614B
+1.18%-7.37%+23.64%+65.03% 431B
+1.66%-0.17%+41.39%+36.34% 353B
+0.72%-3.11%+31.66%+39.90% 293B
+3.29%-7.61%+8.15%+11.46% 245B
-4.30%-14.08%-5.05%-46.77% 210B
+5.58%-0.78%+29.17%+60.32% 210B
+0.64%+0.69%+18.11%+71.90% 168B
Average +0.60%-5.02%+26.80%+48.58% 390.92B
Weighted average by Cap. +1.59%-5.89%+33.87%+70.76%

Financials

2026 *2027 *
Net sales 106M 122M 99.11M 91.04M 172M 11.64B 174M 1.17B 457M 5.82B 460M 450M 19.29B 176M 203M 164M 151M 285M 19.28B 288M 1.93B 756M 9.64B 761M 745M 31.94B
Net income 1.27M 1.47M 1.19M 1.09M 2.06M 140M 2.09M 14.01M 5.48M 69.8M 5.51M 5.39M 231M 49.6M 57.12M 46.25M 42.48M 80.35M 5.43B 81.23M 545M 213M 2.72B 215M 210M 9B
Net Debt -28.5M -32.82M -26.57M -24.41M -46.17M -3.12B -46.67M -313M -122M -1.56B -123M -121M -5.17B -28.81M -33.17M -26.86M -24.67M -46.66M -3.16B -47.17M -317M -124M -1.58B -125M -122M -5.23B
Logo COSMO Pharmaceuticals SA
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-